Acclaimed Filmmaker Dr. Bob Gordon Joins Immorta Bio Advisory Board

Immorta Bio Inc. has announced that renowned filmmaker and creative director Dr. Bob Gordon, JD, has joined its Strategic Advisory Board. This addition aims to enhance the company’s efforts in advancing therapies targeting the biology of aging. The announcement was made on February 18, 2026, in Miami, where the pioneering longevity biotechnology firm is based.

Dr. Gordon brings an impressive background in creative leadership, having produced over 1,200 commercials across more than 40 countries. His extensive experience includes collaborations with Fortune 500 companies such as Nike, Coca-Cola, and BMW. Additionally, he is recognized for developing the first global campaign for Siemens and the iconic “Taste the World, Taste Heineken” campaign for Heineken. His work has received numerous accolades, including an award for the Best Pharmaceutical Campaign for Sanofi’s Plavix, and his Visa commercial “Kangaroo Dreams” is featured in the permanent collection of the Museum of Modern Art (MoMA) in New York.

Before his venture into filmmaking, Dr. Gordon earned a Juris Doctor and practiced law briefly, which offers him a unique perspective in navigating highly regulated industries. This multidisciplinary background is expected to benefit Immorta Bio as it communicates its vision to a broader audience.

According to Boris N. Reznik, PhD, Chairman and CEO of Immorta Bio, “Bob Gordon’s exceptional ability to translate complex concepts into compelling visual narratives will be invaluable as we communicate the transformative potential of targeting aging biology.” His sentiments were echoed by Thomas Ichim, PhD, President and Chief Scientific Officer, who highlighted their previous collaborations and noted Dr. Gordon’s unparalleled combination of creative vision and execution.

In his own words, Dr. Gordon expressed enthusiasm about joining Immorta Bio, stating, “Immorta Bio is pursuing one of the most important scientific frontiers of our time – immortality. I am excited to support the Company in bringing this vision to global audiences.”

Immorta Bio is making strides in the longevity sector through its innovative SenoVax senolytic immunotherapy and proprietary StemCellRevivify regenerative platform. The company focuses on addressing diseases of aging at their biological root by targeting key drivers of aging. Recent preclinical results have shown promise across various areas, including oncology and organ regeneration, aligning with the company’s mission of treating aging as a disease.

The integration of Dr. Gordon into Immorta Bio’s advisory board marks a significant step towards bridging the gap between scientific innovation and effective communication. As the field of longevity biotechnology continues to evolve, the company is poised to leverage his extensive experience to further its objectives.

For more information, visit Immorta Bio’s official website at [https://www.immortabio.com](https://www.immortabio.com).